MXPA02003484A - Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. - Google Patents

Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.

Info

Publication number
MXPA02003484A
MXPA02003484A MXPA02003484A MXPA02003484A MXPA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A
Authority
MX
Mexico
Prior art keywords
synergistic combinations
receptor antagonist
gaba analog
treatment
present
Prior art date
Application number
MXPA02003484A
Other languages
English (en)
Inventor
Singh Lakhbir
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA02003484A publication Critical patent/MXPA02003484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona metodos de tratamiento usando combinaciones sinergisticas de un antagonista de receptor de NK1 y un analogo de GABA, y composiciones farmaceuticas y productos que contienen el antagonista de receptor de NK1 y el analogo de GABA. La presente invencion tambien proporciona el uso de un antagonista de receptor de NK1 y un analogo de GABA para la fabricacion de un medicamento para el tratamiento o la prevencion del dolor cronico.
MXPA02003484A 1999-10-07 2000-10-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. MXPA02003484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
MXPA02003484A true MXPA02003484A (es) 2004-09-10

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003484A MXPA02003484A (es) 1999-10-07 2000-10-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.

Country Status (38)

Country Link
EP (2) EP1221950B1 (es)
JP (2) JP2003510356A (es)
KR (1) KR20020060192A (es)
CN (1) CN1387434A (es)
AP (1) AP2002002501A0 (es)
AR (1) AR029646A1 (es)
AT (1) ATE269072T1 (es)
AU (2) AU7663300A (es)
BG (1) BG106548A (es)
BR (1) BR0014598A (es)
CA (1) CA2385930A1 (es)
CO (1) CO5280195A1 (es)
CR (1) CR6614A (es)
CZ (1) CZ20021116A3 (es)
DE (1) DE60011650T2 (es)
DK (1) DK1221950T3 (es)
EA (1) EA004266B1 (es)
EE (1) EE200200185A (es)
ES (1) ES2220542T3 (es)
GT (1) GT200000166A (es)
HR (1) HRP20020286A2 (es)
HU (1) HUP0203466A3 (es)
IL (1) IL148965A0 (es)
IS (1) IS6318A (es)
MA (1) MA26826A1 (es)
MX (1) MXPA02003484A (es)
NO (1) NO20021625L (es)
NZ (1) NZ517949A (es)
OA (1) OA12063A (es)
PA (1) PA8504301A1 (es)
PE (1) PE20010708A1 (es)
PL (1) PL357498A1 (es)
PT (1) PT1221950E (es)
SK (1) SK4542002A3 (es)
TR (1) TR200200913T2 (es)
UY (1) UY26376A1 (es)
WO (2) WO2001024792A1 (es)
ZA (1) ZA200202675B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2003267732A1 (en) * 2002-10-08 2004-05-04 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
EP3946260A1 (en) 2019-03-26 2022-02-09 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
WO1998015277A2 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
PT1221950E (pt) 2004-08-31
HRP20020286A2 (en) 2003-08-31
NO20021625D0 (no) 2002-04-05
OA12063A (en) 2006-05-03
EP1221950A1 (en) 2002-07-17
WO2001024792A9 (en) 2002-09-06
ZA200202675B (en) 2003-04-15
IS6318A (is) 2002-03-21
TR200200913T2 (tr) 2002-09-23
MA26826A1 (fr) 2004-12-20
EA200200303A1 (ru) 2002-08-29
PE20010708A1 (es) 2001-07-27
ATE269072T1 (de) 2004-07-15
CN1387434A (zh) 2002-12-25
SK4542002A3 (en) 2003-09-11
CO5280195A1 (es) 2003-05-30
JP2003510355A (ja) 2003-03-18
DE60011650T2 (de) 2005-07-14
DK1221950T3 (da) 2004-09-20
IL148965A0 (en) 2002-11-10
PA8504301A1 (es) 2002-08-26
CA2385930A1 (en) 2001-04-12
AP2002002501A0 (en) 2002-06-30
BR0014598A (pt) 2002-06-11
KR20020060192A (ko) 2002-07-16
EP1233766A1 (en) 2002-08-28
WO2001024791A1 (en) 2001-04-12
AU1696201A (en) 2001-05-10
UY26376A1 (es) 2000-12-29
GT200000166A (es) 2002-03-30
EP1221950B1 (en) 2004-06-16
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
CZ20021116A3 (cs) 2003-05-14
EE200200185A (et) 2003-04-15
WO2001024792A1 (en) 2001-04-12
HUP0203466A3 (en) 2005-03-29
ES2220542T3 (es) 2004-12-16
DE60011650D1 (de) 2004-07-22
JP2003510356A (ja) 2003-03-18
HUP0203466A2 (hu) 2003-02-28
CR6614A (es) 2003-12-04
BG106548A (en) 2002-12-29
NO20021625L (no) 2002-04-05
AR029646A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
AU2003301190A1 (en) Administration of capsaicinoids
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
RS20050344A (en) Treatment for hemorrhagic shock
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
EP0934065A4 (en) PHARMACEUTICAL COMPOUNDS
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP0869786A4 (en) PHARMACEUTICAL COMPOUNDS
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
GB9917290D0 (en) Pharmaceutical composition
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DOP2000000076A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un análogo estructural de gaba. (synergistic combinations of a nki receptor antagonist and a gaba structural analog)
ECSP003696A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba
UA36137A (uk) Спосіб лікування хворих на хронічне легеневе серце
MX9707719A (es) Preparado en combinacion que contiene tramadol y un antagonista del canal de calcio.
SV2002000189A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba
SI1408966T1 (sl) Sinergistične farmacevtske kombinacije za preprečevanje ali zdravljenje diabetesa

Legal Events

Date Code Title Description
FG Grant or registration